So far, the company recruited around 500 patients in the trial, whose primary endpoint is overall survival.
Merck Serono Oncology Global Clinical Development Unit senior vice president Oliver Kisker said completing patient enrollment in the CENTRIC study is a very exciting milestone for them and takes them a step closer to evaluating the efficacy and safety of cilengitide in patients with this aggressive form of brain cancer.